|
OBI Pharma transfers exclusive rights to develop, commercialize Dificid (fidaxomicin)
OBI Pharma, Inc. today announced an agreement with MSD, known as Merck in the United States and Canada, through a subsidiary transferring exclusive rights to develop and commercialize Dificid (fidaxomicin) in Taiwan to MSD.
More... |
| All times are GMT -7. The time now is 02:43 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021